UNASSIGNED: Ipilimumab is an anti- @entity4386 antibody which has recently been approved in Europe as a monotherapy in the treatment of @entity320 . We report a single-center study among @entity1 treated within a Temporary Authorization for Use (TAU) protocol. We also performed a review of the literature involving expanded access program studies with a focus on factors associated with @entity1349 ( @entity1349 ). @entity1 and methods: This retrospective, observational study included @entity1 between June 2010 and July 2011 with a diagnosis of non-resectable stage III or IV @entity320 with at least one previous line of chemotherapy. Treatment consisted of four courses of ipilimumab at a dose of 3mg/kg every three weeks. Results: 45 @entity1 were included, among whom 23 (51%) had brain metastases. 33 (71%) of the @entity1 completed the induction phase. The best overall response rate (BORR) was 13% and median @entity1349 ( @entity1349 ) was 8 months (95%CI: 7 to 12). @entity1349 was not different between @entity1 with brain metastases at baseline and those without (p  =  0.10), regardless of @entity817 @entity8554 status (p  =  0.61). @entity1349 was poorer in @entity1 who were being treated with @entity288 at baseline (p<0.001) or with LDH at baseline > 500 UI/ml (p  =  0.008). Conclusion: A subset of @entity1 most likely to benefit from ipilimumab should be defined. In our series we found a negative association of baseline corticosteroids with @entity1349 . Unlike high LDH levels, @entity817 @entity8554 status and brain metastases should not be barriers to the initiation of treatment.

Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in XXXX : negative impact of baseline corticosteroids.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8554 :: ('p|SUB|V|600|E', 'ProteinMutation') :: ['V600 E', 'V600E'] @entity4386 :: ('1493', 'Gene') :: ['CTLA-4'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticoids']
@entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']
